IDT Sample Clauses

IDT. In August 2010, we entered into a license agreement with Integrated DNA Technologies, or IDT, related to the use of blocked primers in combination with HDA. The term of this license agreement extends until the expiration of all the patents associated with the licensed patent rights, or until such time as we elect to terminate with 90 days’ notice. The license is exclusive to the fields of amplification utilizing HDA and detection of diagnostic targets in human in-vitro diagnostic testing, but is non-exclusive to all oncology and human papilloma virus targets or markers. These technologies have resulted in four pending U.S. patent applications and one issued European patent. We pay a royalty fee for the license of this technology based on a percentage of our “Net Sales” of products using these technologies (as defined in the license agreement). Schedule 3(v)(v) See Schedule 3(v)(i). Schedule 3(w) – Absence of Litigation Wrongful termination complaint filed in the United States District Court in and for the District of Utah, Central Division by a former employee, Xxxxxxxxx Xxxxxx, against Great Basin Scientific, Inc. on June 15, 2016. Schedule 3(aa)(i) - Intellectual Property Rights Great Basin Owned Patents Patent Title U.S. 8,637,250 Systems and methods for point of care amplification and detection of nucleic acids (HDA, methods) US 14/108,630 Systems and methods for point of care amplification and detection of nucleic acids (continuation, HDA, kit claims) CA2715890 Systems and methods for point of care amplification and detection of nucleic acids (general method) EP2245184 Systems and methods for point of care amplification and detection of nucleic acids (HDA) EP15182599.9 (divisional from ‘84) Systems and methods for point of care amplification and detection of nucleic acids (general method) EP08853920.0 Methods and compositions for amplifying a detectable signal U.S. 8,574,833 Methods and compositions for amplifying a detectable signal (nucleic acid targets, methods/kits/system) US 9,200,312 Methods and compositions for amplifying a detectable signal (continuation, generalize target, kit/system) US 9,359,637 Methods and compositions for amplifying a detectable signal (continuation, generalize target, methods of use/prep) US 14/949,240 Methods and compositions for amplifying a detectable signal (continuation, generalize target, methods of use/prep) CA2705984 Methods and compositions for amplifying a detectable signal US 13/911,878 Analyzer and Disposable...
Sample 1
AutoNDA by SimpleDocs
IDT. Phase 2. The attacker runs A2 on the input of state and the output of the challenger. A2 can make the same kinds of query as those in Phase 1. But A2 is not allowed to make a Reveal query on the input of Πt or its partner oracle. A2 terminates by outputting a guess bit bj. Suppose that there are x aborted oracles at the end of the game where x < m . The attacker’s advantage in this game is defined to be AdvA(U ) = j( n−1 t F x, Pr(b = bj)), where the function Fj is defined as follows: on the input of an integer a
Sample 1
IDT. Reveal(Π), where Π is an accepted oracle. A 1 terminates by outputting an accepted oracle Πt and some state infor- mation state.
Sample 1
IDT. In August 2010, we entered into a license agreement with Integrated DNA Technologies, or IDT, related to the use of blocked primers in combination with HDA. The term of this license agreement extends until the expiration of all the patents associated with the licensed patent rights, or until such time as we elect to terminate with 90 days’ notice. The license is exclusive to the fields of amplification utilizing HDA and detection of diagnostic targets in human in-vitro diagnostic testing, but is non-exclusive to all oncology and human papilloma virus targets or markers. These technologies have resulted in four pending U.S. patent applications and one issued European patent. We pay a royalty fee for the license of this technology based on a percentage of our “Net Sales” of products using these technologies (as defined in the license agreement). Schedule 4(d) - Use of Proceeds Net proceeds will be used for general operating purposes. Schedule 7(v)
Sample 1
IDT. IDT will maintain, at all times during the Term of this Agreement and for a period of [***] thereafter, a general third party liability insurance including Products liability insurance policy, with a per claim limit of at least [***], and an aggregate limit of at least [***]. In addition, IDT shall maintain an environmental liability insurance policy in accordance with the EU Directive 2004/35/EC, as amended. Without limiting the preceding sentence, IDT shall provide Valneva with at least [***] Notice prior to termination of or reduction in said coverage.
Sample 1
IDT. In August 2010, we entered into a license agreement with Integrated DNA Technologies, or IDT, related to the use of blocked primers in combination with HDA. The term of this license agreement extends until the expiration of all the patents associated with the licensed patent rights, or until such time as we elect to terminate with 90 days’ notice. The license is exclusive to the fields of amplification utilizing HDA and detection of diagnostic targets in human in-vitro diagnostic testing, but is non-exclusive to all oncology and human papilloma virus targets or markers. These technologies have resulted in four pending U.S. patent applications and one issued European patent. We pay a royalty fee for the license of this technology based on a percentage of our “Net Sales” of products using these technologies (as defined in the license agreement). Schedule 3(ee) – Internal Accounting and Disclosure Controls As stated in our Form 10-K for the year ended December 31, 2015, we identified a material weakness in our system of internal control over financial reporting relating to processes and controls over properly identifying and accounting for transactions of a complex or non-routine nature. Management also identified certain design deficiencies relating to segregation of duties, review and approval, and verification procedures, primarily resulting from the limited number of our accounting staff available to perform such procedures. Additionally, management identified certain design deficiencies to access over information systems. Management plans to implement a number of initiatives to address the ineffective design of the system of internal control over financial reporting, including but not limited to the following: • Employ additional staff in our finance and accounting department to perform the required tasks to maintain an optimal segregation of duties, review and approval and verification procedures and provide optimal levels of oversight. • Continue to work closely with our independent SOX consultants to help improve the overall design of our system of internal control over financial reporting and promptly remediate any identified weaknesses • Continue to evaluate control procedures on an ongoing basis, and, where possible modify those control procedures to improve oversight. • Continue to engage independent consultants to assist accounting staff with processing transactions and preparing financial statements, especially related to complex transactions. W...
Sample 1
IDT. Phase 2. The attacker runs A2 on the input of state and the output of the challenger. A2 can make the same kinds of query as those in Phase 1. But A2 is not allowed to make a Reveal query on the input of Πt or its partner oracle. A2 terminates by outputting a guess bit b′. Suppose that there are x aborted oracles at the end of the game where x < m . The attacker’s advantage in this game is defined to be AdvA(U )= ′( n−1 t F x, Pr(b = b′)), where the function F′ is defined as follows: on the input of an integer a (a < n) and a value b (0 ≤ b ≤ 1), F′(a, b) is computed as: ′ ,⎨ 0, if b ≤ 1+Σ a(n−1)+1 pj F Σ −1+ pj (a, b)= , b − a(n 1)+1 j=1 j=1 , otherwise
Sample 1
AutoNDA by SimpleDocs
IDT. Reveal(M), where M is an accepted oracle. A 1 terminates by outputting an accepted oracle Mt and some state infor- mation state.
Sample 1

Related to IDT

  • Cornerstone shall notify the LLC and confirm such advice in writing (i) when the filing of any post-effective amendment to the Registration Statement or supplement to the Prospectus is required, when the same is filed and, in the case of the Registration Statement and any post-effective amendment, when the same becomes effective, (ii) of any request by the Securities and Exchange Commission for any amendment of or supplement to the Registration Statement or the Prospectus or for additional information and (iii) of the entry of any stop order suspending the effectiveness of the Registration Statement or the initiation or threatening of any proceedings for that purpose, and, if such stop order shall be entered, Cornerstone shall use its best efforts promptly to obtain the lifting thereof.

  • Baxter and Nexell shall cooperate in any action taken by a third party solely involving a nullity action, opposition, reexamination or any other action taken by such third party alleging the invalidity or unenforceability of any Licensed Intellectual Property. Both parties agree to share equally in the cost of the defense of such Licensed Intellectual Property.

  • Collaboration Management Promptly after the Effective Date, each Party will appoint a person who will oversee day-to-day contact between the Parties for all matters related to the management of the Collaboration Activities in between meetings of the JSC and will have such other responsibilities as the Parties may agree in writing after the Effective Date. One person will be designated by Merck (the “Merck Program Director”) and one person will be designated by Moderna (the “Moderna Program Director,”) together will be the “Program Directors”. Each Party may replace its Program Director at any time by notice in writing to the other Party. Any Program Director may designate a substitute to temporarily perform the functions of that Program Director by written notice to the other Party. The initial Program Directors will be: For Moderna: [***] For Merck: [***]

  • Licensee Licensee represents and warrants that:

  • API If the Software offers integration capabilities via an API, your use of the API may be subject to additional costs or Sage specific policies and terms and conditions (which shall prevail in relation to your use of the API). You may not access or use the API in any way that could cause damage to us or the Software, or in contravention of any applicable laws. We reserve the right in our sole discretion, to: (i) update any API from time to time; (ii) place limitations around your use of any API; and (iii) deny you access to any API in the event of misuse by you or to otherwise protect our legitimate interests.

  • AMD AMD shall keep records in sufficient detail to enable FoundryCo to determine that AMD has complied with its second sourcing limitations in Section 2.1(b) and its GPU Product volume sourcing commitments in Section 2.1(c). AMD shall permit said records to be inspected, at FoundryCo’s expense, upon reasonable advance notice, during regular business hours by an independent auditor selected by FoundryCo and approved by AMD, which approval shall not be unreasonably withheld. The audit shall be for the purpose of verifying that AMD has complied with its second source restrictions in Section 2.1(b) and its GPU Product sourcing commitments in Section 2.1(c). Inspections conducted under this Section 8.1(b) shall be at FoundryCo’s expense, unless AMD has a non-compliance variance adverse to FoundryCo of [****] percent ([****]%) or more of (i) the relevant [****] percent ([****]%) second source restriction or (ii) the GPU Minimum Percentage for the applicable audited period, in which case AMD shall bear the reasonable expenses of such audit.

  • Client Client agrees to indemnify, defend, and shall hold harmless Consultant and /or his agents, and to defend any action brought against said parties with respect to any claim, demand, cause of action, debt or liability, including reasonable attorneys' fees to the extent that such action is based upon a claim that: (i) is true, (ii) would constitute a breach of any of Client's representations, warranties, or agreements hereunder, or (iii) arises out of the negligence or willful misconduct of Client, or any Client Content to be provided by Client and does not violate any rights of third parties, including, without limitation, rights of publicity, privacy, patents, copyrights, trademarks, trade secrets, and/or licenses.

  • IBM Credit may in its sole discretion from time to time decide the amount of credit IBM Credit extends to Customer, notwithstanding any prior course of conduct between IBM Credit and Customer. IBM Credit may combine all of its advances to make one debt owed by Customer.

  • Services to the Corporation Agent will serve, at the will of the Corporation or under separate contract, if any such contract exists, as a director of the Corporation or as a director, officer or other fiduciary of an affiliate of the Corporation (including any employee benefit plan of the Corporation) faithfully and to the best of his ability so long as he is duly elected and qualified in accordance with the provisions of the Bylaws or other applicable charter documents of the Corporation or such affiliate; provided, however, that Agent may at any time and for any reason resign from such position (subject to any contractual obligation that Agent may have assumed apart from this Agreement) and that the Corporation or any affiliate shall have no obligation under this Agreement to continue Agent in any such position.

Time is Money Join Law Insider Premium to draft better contracts faster.